To provide a compound excellent in cancer cell growth inhibitory activity, metabolic stability, solubility, etc.
A pharmaceutical contains at least one kind of substance selected from a group consisting of a carboxamide derivative of formula [I] (L1, L2 and L3 are each an alkylene or nonexistent; [A] is hydroxy or an electron donating group-substituted aromatic ring; [B] is a monocyclic ring or a condensed ring; [C] is H or hydroxy; and [D] is a monocyclic ring or a condensed ring), its tautomer, its stereoisomer, and a salt thereof as an active ingredient. The derivative has excellent HDAC inhibitory activity and therefore is expected to be used for an anticancer agent or various applications other than the anticancer agent, such as a treating agent and/or an improving agent for disease related to cell growth, an efficacy enhancing agent for gene therapy, a megalocardia improving agent, an immunosuppressant, a pharmaceutical for retarding or inhibiting neurodegenerative disease, including Huntington's disease, caused by expansion of a polyglutamine repetitive sequence.
NAGAOKA YASUO
MAEDA TAIJI
| JP2005508905A | 2005-04-07 | |||
| JPH11269146A | 1999-10-05 |
| WO2005034880A2 | 2005-04-21 | |||
| WO2004069823A1 | 2004-08-19 | |||
| WO2005030705A1 | 2005-04-07 |
Next Patent: METHOD FOR PRODUCING (METH)ACRYLATE ESTER